Blautia Strains for Gut Microbiota Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for gastrointestinal disorders such as diarrhea and constipation lack specific bacterial strains linked to disease treatment, and existing patent applications fail to provide effective solutions for modulating gut microbiota to address these conditions.
Innovation Solution
Development of compositions comprising bacterial strains from the genus Blautia, specifically Blautia hydrogenotrophica, Blautia stercoris, and Blautia wexlerae, for oral administration to treat or prevent diarrhea and constipation, particularly in patients with IBS, Crohn's disease, and ulcerative colitis, by modulating the gut microbiota.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If specific bacterial strains are used to treat gastrointestinal disorders, then therapeutic efficacy is improved, but lack of specific strain identification prevents effective treatment
Solution Approach 1:
The patent employs 16S rRNA gene sequencing to identify and characterize specific bacterial strains from the genus Blautia. This molecular identification method provides feedback on the precise strain composition of the microbiota, enabling selection of strains with proven therapeutic efficacy for treating gastrointestinal disorders such as IBS, Crohn's disease, and ulcerative colitis.
Solution Approach 2:
The patent changes the parameter of bacterial identification from generic genus-level classification to specific strain-level identification using 16S rRNA sequencing. This parameter change allows differentiation between strains with varying therapeutic properties, thereby improving treatment reliability by selecting strains with documented efficacy for specific gastrointestinal conditions.
2Object-affected harmful factors
If Blautia strains are administered to modulate gut microbiota, then diarrhea and constipation symptoms are reduced, but mechanism of action requires further characterization
Solution Approach 1:
The patent replaces empirical observation of symptom relief with molecular characterization techniques to understand the mechanism of action. By using 16S rRNA sequencing and genomic analysis, the patent substitutes mechanical/symptomatic assessment with molecular-level understanding of how Blautia strains modulate gut microbiota composition and function to reduce diarrhea and constipation symptoms.
Data Source
AI summary
The invention provides compositions comprising one or more bacterial strains for treating preventing diarrhea and/or constipation.